COVID-19 Diseases, Clinical Manifestations and Treatment Guideline

Volume 7, Issue 4, August 2022     |     PP. 241-261      |     PDF (232 K)    |     Pub. Date: June 26, 2022
DOI: 10.54647/cm32834    66 Downloads     3224 Views  

Author(s)

Youngah Choi, Department of Internal Medicine, Seoul Metropolitan Seobuk Hospital, Seoul, Korea
Eun-Hyang Song, Department of Neurology, Seoul Metropolitan Seobuk Hospital, Seoul, Korea
Bu-Yeon Kim, Department of Thoracic Surgery, Seoul Metropolitan Seobuk Hospital, Seoul, Korea
Hyun-Joo Jin, Department of Pediatrics, Seoul Metropolitan Seobuk Hospital, Seoul, Korea
Shin-Ae Park, Department of Family Medicine, Seoul Metropolitan Seobuk Hospital, Seoul, Korea

Abstract
From March 2nd, 2020th, Seoul Metropolitan Seobuk hospital started as a hospital mainly for COVID-19 infections and has been continuously treating COVID-19 inpatients until now, May 8th, 2022th. From the beginning of February, 2020th, to May 8th, 2022th, the total cumulative number of confirmed COVID-19 cases in Korea was 17, 544,398, the death toll was 23,360, and the mortality rate is 0.13%. The Korean quarantine system hospitalizes COVID-19 patients in the early stages of the (COVID-19) disease. We believe that it is due to this system that Korea has been able to keep a considerably low death rate compared to many other countries. It is believed that the current quarantine system in Korea, which allows patients to be treated with Veklury (antiviral agent IV infusion drug)in hospitals at the initial stage of diagnosis, or early oral Paxlovid (antiviral agent) administration at home treatment also lowered the death rate from COVID-19. Our study and data want to clarify the importance of early phase treatment of antiviral agents about COVID-19 regardless of underlying disease patterns and newly diagnosed COVID-19 related disease patterns and age differences. In this paper, with data on 3,827 patients hospitalized from March 2, 2020th to December 31, 2021th at Seoul Metropolitan Seobuk hospital, this paper analyzes the underlying disease patterns of patients and newly diagnosed disease patterns, by analyzing clinical features and medication history of the patients who were hospitalized with COVID-19 in this hospital. We want to clarify the importanece of early treatment of antiviral agents about COVID-19 regardless of underlying disease patterns and age differences. The most important thing is that as early as possible Veklury (Remdesivir) should be administered in early period of COVID-19 disease. Until last year, our Veklury administration guideline was as soon as early administration when oxygen saturation drops under 94%. Nowadays, our Veklury administration guideline change to give Veklury administration or Paxlovid right after the diagnosis of COVID-19 disease. It is believed that the current quarantine system in Korea, which allows patients to be treated with Veklury in hospitals at the initial stage of diagnosis, or early oral Paxlovid administration possible at home treatment. Because all antiviral agents costs and hospital treatment costs are free charge to COVID-19 patients because it was covered by government. This Korean quarantine system also helpful to lower the death rate from COVID-19.

Keywords
The importance of early phase administration of Veklury or Paxlovid regardless of underlying patients’ condition

Cite this paper
Youngah Choi, Eun-Hyang Song, Bu-Yeon Kim, Hyun-Joo Jin, Shin-Ae Park, COVID-19 Diseases, Clinical Manifestations and Treatment Guideline , SCIREA Journal of Clinical Medicine. Volume 7, Issue 4, August 2022 | PP. 241-261. 10.54647/cm32834

References

[ 1 ] Giuseppe Lisco etc , COVID-19 and Endocrine System : A Comprehensive Review on the Theme, Journal of Clinical Medicine, 2021, 10, 2920
[ 2 ] Mehdi Ghasemi etc, SARS-CoV-2 and Acute Cerebrovascular Events : An Overview , Journal of Clinical Medicine, 2021, 10, 3349 ,.
[ 3 ] Talida Georgiana Cut etc. Article: Spontaneous Pneumomediastinum, Pneumothorax, pneumopericardium and Subcutaneous Emphysema – Not So Uncommon Comlications in Patients with COVID-19 Pulmonary Infection – A Series of Cases, Journal of Clinical Medicine, 2021, 10, 1346,
[ 4 ] Chieh-Chen Wu etc. Article: Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19. Journal of Clinical Medicine, 2021, 10, 1450,
[ 5 ] Andreas Rank etc. Article: One Year after Mild COVID-19; The Majority of Patients Maintain Specific Immunity , But One in Four Still Suffer from Long term Symptoms. Journal of Clinical Medicine, 2021, 10, 3305,
[ 6 ] Brunella Posteraro etc. Article: Risk Factors for Mortality in Adult COVID-19 Patients Who Develop Bloodstream Infections Mostly Caused by Antimicrobial-Resistant Organisms : Analysis at a Large Teaching Hospital in Italy, Journal of Clinical Medicine, 2021, 10, 1752 ,
[ 7 ] Fabiola Atzeni etc. Review: The Rheumatology Drugs for COVID-19 Management : Which and When ? Journal of Clinical Medicine, 2021, 10, 783,
[ 8 ] Mehdi Ghasemi etc. Review: SARS-CoV-2 and Acute Cerebrovascular Events: An Overview, Journal of Clinical Medicine, 2021, 10, 3349 ,
[ 9 ] Joon-Young Song etc Article: Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19 : A Randomized, Open-Label, Phase 2 Trial, Journal of Clinical Medicine, 2021, 10, 3545,.
[ 10 ] National medical center/ Office for the central infectious disease hospital , South Korea, 2020
[ 11 ] Fabiola Atzeni etc. The Rheumatology Drugs for COVID-19 management : Which and When ? Journal of Clinical Medicine, 2021, 10, 783,
[ 12 ] Monika Gudoswka-Sawcwuk etc. The role of Neuropilin-1 ( NRP-1) in SARS-CoV-2 infection : Review Journal of Clinical Medicine, 2021, 10, 2772,
[ 13 ] Md. Mohaimenul Islam etc. A state of the Art Survey on Artificial Intelligence to Fight COVID-19, Journal of Clinical medicine, 2021, 10, 1961,
[ 14 ] Afshin Derakhshani etc. Arginas1( ARG1) as an Un-Regulated Gene in COVID-19 Patients: A Promise Marker in COVID-19 Immunopathy, Journal of Clinical Medicine. 2021, 10, 1051,
[ 15 ] Youngah Choi etc. The importance of Early Treatment for COVID-19, American Journal of Biomedical Science & Research ,2021-14(4)
[ 16 ] Youngah Choi etc. COVID-19 Disease Cinical Manifestations and Treatment Analysis , Science Journal of Clinical Medicine 2022:11(1):25-32
[ 17 ] Joon-Young Song etc. Ciclesonide inhaler Treatment for Mild- to-Moderate COVID-19: A Randomized,Open –Label, Phase 2 Trial, Journal of Clinical Medicine. 2021,10,3545